This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Autoimmune Disease Therapeutics Market

Therapeutics are the New Elixir to Cure Autoimmune Diseases. Unveil more Insights with FMI's Analysis

Autoimmune Disease Therapeutics Market by Drug Class, Indication, Sales Channel & region - Forecast 2022 - 2032

Autoimmune Disease Therapeutics Market Outlook (2022-2032)

[308 Pages Report] The global autoimmune disease therapeutics market is likely to be valued at US$ 68,410.54 million in 2022 and is predicted to secure a moderate-paced CAGR of 5.6% during the forecast period. The market is expected to grow at a value of US$ 1,17,967.44 million by 2032.A historical CAGR of 4.8% has been recorded during the analysis by Future Market Insights.

It is identified that there are more than 80 different types of autoimmune disorders amongst which multiple sclerosis, IBS, lupus, type 1 diabetes, psoriasis, rheumatoid arthritis, and others are the most common forms of autoimmune diseases.

Report Attribute

Details

Autoimmune Disease Therapeutics Market Value (2022)

US$ 68,410.54 Million

Autoimmune Disease Therapeutics Market Anticipated Value (2032)

US$ 1,17,967.44 Million

Autoimmune Disease Therapeutics Management Projected Growth Rate (2022-2032)

5.6%

The adoption of autoimmune disease therapeutics insights reveals they are being used as these diseases cause abnormally low activity or overactivity of the immune systems, attacking the body’s own tissues and cells, which need to be treated therapeutically.

It is witnessed that autoimmune diseases decrease the body’s ability to fight foreign agents, and it is more common in women than in men. Therefore, it is anticipated that the autoimmune disease therapeutics market is likely to have significant growth during the forecast period.

Customize this Report

Let us know your requirement to get
100% FREE customization

Prime Factors Driving And Deterring The Market Growth Of Autoimmune Disease Therapeutics

The global market for autoimmune disease therapeutics is expected to have increased growth in the coming years and there are many factors identified that are likely to bolster the market dynamics in a positive direction.

Besides the propelling factors, a number of challenges are also identified. Let us take an in-depth look at the following drivers and restraints.

DRIVERS:

  • Rising Awareness of Autoimmune Diseases: It is anticipated that there is a growing prevalence of autoimmune diseases that are growing the awareness amongst the populace for adopting autoimmune disease therapeutics, boosting the market size.
  • Growing R&D Activities: It is witnessed that there is a growth in research and development activities to foster the use of ideal therapeutics in the market.
  • Emerging Technologies: There are technological advances in the screening procedures, wide availability of therapeutics, and a strong presence of pipeline drugs such as baricitinib, certolizumab, secukinumab, and others are expected to further influence the market growth.
  • Increased Automation: Additionally, the analysis of FMI records increased the automation of laboratories that are leading to a diagnosis of several tests that generate fast and error-free results that further fuel the market growth.

RESTRAINTS:

  • Inadequate Funding: It is identified that in the developing countries there is inadequate funds to flourish adequate adoption and setting up of autoimmune disease therapeutics diagnostics.
  • Non-availability of Treatment: It is anticipated that there is a high cost associated with the treatment of autoimmune diseases and their proper treatments are also unavailable in most countries, which is likely to inhibit the market growth.
  • Advent of Alternative Technologies: The analysis of FMI unravels the factor that there are a lot of emerging technologies, which are being used as an alternative to therapeutics and are likely to curb the growth of the autoimmune disease therapeutics market.

Regional Outlook

How is North American Autoimmune Disease Therapeutics Market Performing?

North America is projected to dominate the global autoimmune disease therapeutics market during the forecast period. Currently, the region is accountable for 38.0% of the total market share of autoimmune disease therapeutics.

The growth in the North American region can be attributed to:

  • Growing prevalence of various forms of autoimmune disorders in the region.
  • Government initiatives such as the Affordable Care Act and Patient Protection Act are further fueling the growth of the market size of autoimmune disease therapeutics.
  • Increasing healthcare expenditure in this region is also expected to drive the overall autoimmune disease therapeutics market in North America.

Growth Outlook of Europe Autoimmune Disease Therapeutics Market

Europe is projected to have a slow-paced growth during the forecast period, yet it will hold a significant share of the market. At present, the European region is accountable for 18.0% of the total market share of autoimmune disease therapeutics.

The growth can be attributed to:

  • Increased penetration of new technologies such as potable diagnostic equipment and novel biomarkers are contributing largely to the market growth of Europe.
  • A large number of lucrative growth opportunities and improving healthcare infrastructure are likely to foster growth in Europe.
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Start-Up Ecosystem

The start-up companies in the autoimmune disease therapeutics market are intensifying their focus on frequent innovations and indulging themselves in mergers and acquisitions to develop effective therapeutic solutions for the end-users.

Three Start-Ups Gaining Traction in The Market

Viela Bio – The US-based start-up creates a novel therapeutic to treat neuromyelitis optica spectrum disorder, a neuroinflammatory disorder that causes irreversible blindness and paralysis. UPLIZNA targets the aquaporin-4 antibody in adult patients. A combination of immunosuppressive therapies with UPLIZNA helps patients overcome this rare disease with minimal side effects, including urinary tract infection and influenza.

Immundnz – This Bristish start-up develops COMPIT, an in vitro immune response platform to understand responses in autoimmune disorders. The platform is versatile and helps analyze various parameters including cell viability and cytotoxicity. COMPIT consists of a variety of immune and protein assays that are customizable according to any experimental model to study drug immunology or immune safety.

Landos Biopharma – The Swedish start-up is working on novel therapeutic drugs to treat gastrointestinal immune disorders. The start-up’s lead candidate BT-11, an oral therapeutic drug for treating ulcerative colitis, is currently undergoing Phase II clinical trials. BT-11 activates the lanthionine synthetase C-like protein 2 (LANCL2) pathway, which plays a pivotal role in metabolism and immune response.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Competitive Landscape

Key Market Players Revolutionizing the Autoimmune Disease Therapeutics Market

The market players are focusing on organic growth strategies such as product launches, product approvals, and other such patents and events. They are anticipated to have lucrative growth opportunities in the future with rising demand for autoimmune disease drugs in the global market.

Recent Developments

  • Ventus Therapeutics is a biopharmaceutical company discovering and developing novel small molecule medicines that is targeting the innate immune system to treat autoimmune diseases, inflammatory diseases, and cancer.
  • ImmuneID is a precision immunology company that is using its genome-wide, high-throughput platform to provide a comprehensive understanding of individual immune responses. They are developing targeted immunological-based biologics using a unique oral delivery platform.

Key companies identified are

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca Plc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • UCB S.A.

Report Scope

Report Attribute

Details

Growth Rate

CAGR of 5.6% from 2022 to 2032

Base Year for Estimation

2021

Historical Data

2016-2021

Forecast Period

2022-2032

Quantitative Units

Revenue in US$ million and CAGR from 2022-2032

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis

Segments Covered

  • Drug Class
  • Indication
  • Sales Channel
  • Region

Regions Covered

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa

Key Countries Profiled

  • U.S
  • Canada
  • Brazil
  • Argentina
  • Germany
  • U.K
  • France
  • Spain
  • Italy
  • Nordics
  • BENELUX
  • Australia & New Zealand
  • China
  • India
  • ASEAN
  • GCC
  • South Africa

Key Companies Profiled

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca Plc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • UCB S.A.

Customization

Available Upon Request

Key Segments In The Autoimmune Disease Therapeutics Market

By Drug Class Type:

  • Anti-inflammatory
  • Antihyperglycemics
  • NSAIDs
  • Interferons
  • Others

By Indication:

  • Rheumatic Disease
  • Type 1 Diabetes
  • Multiple Sclerosis
  • Inflammatory Bowel Disease
  • Other Indications

By Sales Channel:

  • Hospital Pharmacy
  • Drug Store & Retail Pharmacy
  • Online Store

By Region:

  • North America
  • Latin America
  • Asia Pacific
  • MEA
  • Europe

Frequently Asked Questions

The growth outlook for the autoimmune disease therapeutics market is predicted to advance at a CAGR of 5.6% from 2022 to 2032.

The North American region is anticipated to lead the autoimmune disease therapeutics market during the forecast period.

The autoimmune disease therapeutics market is likely to hold a valuation of US$ 1,17,967.44 million by 2032.

The healthcare sector is the key driver in the autoimmune disease therapeutics market.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2017-2021 and Forecast, 2022-2032

    4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021

    4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Drug Class

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) Analysis By Drug Class, 2017-2021

    5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug Class, 2022-2032

        5.3.1. Immunosuppressant’s

        5.3.2. Anti-Inflammatory Drugs

        5.3.3. Corticosteroids

        5.3.4. Nonsteroidal Anti-inflammatory Drugs

        5.3.5. Biologics

    5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2017-2021

    5.5. Absolute $ Opportunity Analysis By Drug Class, 2022-2032

6. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Mn) Analysis By Distribution Channel, 2017-2021

    6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2022-2032

        6.3.1. Hospitals

        6.3.2. Clinics

        6.3.3. Drug Stores

        6.3.4. Independent Pharmacies

    6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017-2021

    6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022-2032

7. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021

    7.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Europe

        7.3.4. Asia Pacific

        7.3.5. MEA

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    8.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    8.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        8.2.1. By Country

            8.2.1.1. U.S.

            8.2.1.2. Canada

        8.2.2. By Drug Class

        8.2.3. By Distribution Channel

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Drug Class

        8.3.3. By Distribution Channel

    8.4. Key Takeaways

9. Latin America Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Drug Class

        9.2.3. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Class

        9.3.3. By Distribution Channel

    9.4. Key Takeaways

10. Europe Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. U.K.

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Europe

        10.2.2. By Drug Class

        10.2.3. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class

        10.3.3. By Distribution Channel

    10.4. Key Takeaways

11. Asia Pacific Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        11.2.1. By Country

            11.2.1.1. China

            11.2.1.2. Japan

            11.2.1.3. South Korea

            11.2.1.4. India

            11.2.1.5. Malaysia

            11.2.1.6. Singapore

            11.2.1.7. Australia

            11.2.1.8. New Zealand

            11.2.1.9. Rest of APAC

        11.2.2. By Drug Class

        11.2.3. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class

        11.3.3. By Distribution Channel

    11.4. Key Takeaways

12. MEA Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        12.2.1. By Country

            12.2.1.1. GCC Countries

            12.2.1.2. South Africa

            12.2.1.3. Israel

            12.2.1.4. Rest of MEA

        12.2.2. By Drug Class

        12.2.3. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Class

        12.3.3. By Distribution Channel

    12.4. Key Takeaways

13. Key Countries Market Analysis

    13.1. U.S.

        13.1.1. Pricing Analysis

        13.1.2. Market Share Analysis, 2021

            13.1.2.1. By Drug Class

            13.1.2.2. By Distribution Channel

    13.2. Canada

        13.2.1. Pricing Analysis

        13.2.2. Market Share Analysis, 2021

            13.2.2.1. By Drug Class

            13.2.2.2. By Distribution Channel

    13.3. Brazil

        13.3.1. Pricing Analysis

        13.3.2. Market Share Analysis, 2021

            13.3.2.1. By Drug Class

            13.3.2.2. By Distribution Channel

    13.4. Mexico

        13.4.1. Pricing Analysis

        13.4.2. Market Share Analysis, 2021

            13.4.2.1. By Drug Class

            13.4.2.2. By Distribution Channel

    13.5. Germany

        13.5.1. Pricing Analysis

        13.5.2. Market Share Analysis, 2021

            13.5.2.1. By Drug Class

            13.5.2.2. By Distribution Channel

    13.6. U.K.

        13.6.1. Pricing Analysis

        13.6.2. Market Share Analysis, 2021

            13.6.2.1. By Drug Class

            13.6.2.2. By Distribution Channel

    13.7. France

        13.7.1. Pricing Analysis

        13.7.2. Market Share Analysis, 2021

            13.7.2.1. By Drug Class

            13.7.2.2. By Distribution Channel

    13.8. Spain

        13.8.1. Pricing Analysis

        13.8.2. Market Share Analysis, 2021

            13.8.2.1. By Drug Class

            13.8.2.2. By Distribution Channel

    13.9. Italy

        13.9.1. Pricing Analysis

        13.9.2. Market Share Analysis, 2021

            13.9.2.1. By Drug Class

            13.9.2.2. By Distribution Channel

    13.10. China

        13.10.1. Pricing Analysis

        13.10.2. Market Share Analysis, 2021

            13.10.2.1. By Drug Class

            13.10.2.2. By Distribution Channel

    13.11. Japan

        13.11.1. Pricing Analysis

        13.11.2. Market Share Analysis, 2021

            13.11.2.1. By Drug Class

            13.11.2.2. By Distribution Channel

    13.12. South Korea

        13.12.1. Pricing Analysis

        13.12.2. Market Share Analysis, 2021

            13.12.2.1. By Drug Class

            13.12.2.2. By Distribution Channel

    13.13. Malaysia

        13.13.1. Pricing Analysis

        13.13.2. Market Share Analysis, 2021

            13.13.2.1. By Drug Class

            13.13.2.2. By Distribution Channel

    13.14. Singapore

        13.14.1. Pricing Analysis

        13.14.2. Market Share Analysis, 2021

            13.14.2.1. By Drug Class

            13.14.2.2. By Distribution Channel

    13.15. Australia

        13.15.1. Pricing Analysis

        13.15.2. Market Share Analysis, 2021

            13.15.2.1. By Drug Class

            13.15.2.2. By Distribution Channel

    13.16. New Zealand

        13.16.1. Pricing Analysis

        13.16.2. Market Share Analysis, 2021

            13.16.2.1. By Drug Class

            13.16.2.2. By Distribution Channel

    13.17. GCC Countries

        13.17.1. Pricing Analysis

        13.17.2. Market Share Analysis, 2021

            13.17.2.1. By Drug Class

            13.17.2.2. By Distribution Channel

    13.18. South Africa

        13.18.1. Pricing Analysis

        13.18.2. Market Share Analysis, 2021

            13.18.2.1. By Drug Class

            13.18.2.2. By Distribution Channel

    13.19. Israel

        13.19.1. Pricing Analysis

        13.19.2. Market Share Analysis, 2021

            13.19.2.1. By Drug Class

            13.19.2.2. By Distribution Channel

14. Market Structure Analysis

    14.1. Competition Dashboard

    14.2. Competition Benchmarking

    14.3. Market Share Analysis of Top Players

        14.3.1. By Regional

        14.3.2. By Drug Class

        14.3.3. By Distribution Channel

15. Competition Analysis

    15.1. Competition Deep Dive

        15.1.1. Abbott Laboratories

            15.1.1.1. Overview

            15.1.1.2. Product Portfolio

            15.1.1.3. Profitability by Market Segments

            15.1.1.4. Sales Footprint

            15.1.1.5. Strategy Overview

                15.1.1.5.1. Marketing Strategy

        15.1.2. Amgen Inc.

            15.1.2.1. Overview

            15.1.2.2. Product Portfolio

            15.1.2.3. Profitability by Market Segments

            15.1.2.4. Sales Footprint

            15.1.2.5. Strategy Overview

                15.1.2.5.1. Marketing Strategy

        15.1.3. Genentech Inc.

            15.1.3.1. Overview

            15.1.3.2. Product Portfolio

            15.1.3.3. Profitability by Market Segments

            15.1.3.4. Sales Footprint

            15.1.3.5. Strategy Overview

                15.1.3.5.1. Marketing Strategy

        15.1.4. F. Hoffmann-La Roche AG

            15.1.4.1. Overview

            15.1.4.2. Product Portfolio

            15.1.4.3. Profitability by Market Segments

            15.1.4.4. Sales Footprint

            15.1.4.5. Strategy Overview

                15.1.4.5.1. Marketing Strategy

        15.1.5. Merck & Co. Inc.

            15.1.5.1. Overview

            15.1.5.2. Product Portfolio

            15.1.5.3. Profitability by Market Segments

            15.1.5.4. Sales Footprint

            15.1.5.5. Strategy Overview

                15.1.5.5.1. Marketing Strategy

        15.1.6. Bayer Schering Pharma AG

            15.1.6.1. Overview

            15.1.6.2. Product Portfolio

            15.1.6.3. Profitability by Market Segments

            15.1.6.4. Sales Footprint

            15.1.6.5. Strategy Overview

                15.1.6.5.1. Marketing Strategy

        15.1.7. Johnson & Johnson Inc.

            15.1.7.1. Overview

            15.1.7.2. Product Portfolio

            15.1.7.3. Profitability by Market Segments

            15.1.7.4. Sales Footprint

            15.1.7.5. Strategy Overview

                15.1.7.5.1. Marketing Strategy

        15.1.8. Biogen Idec Inc.

            15.1.8.1. Overview

            15.1.8.2. Product Portfolio

            15.1.8.3. Profitability by Market Segments

            15.1.8.4. Sales Footprint

            15.1.8.5. Strategy Overview

                15.1.8.5.1. Marketing Strategy

        15.1.9. GlaxoSmithKline Plc

            15.1.9.1. Overview

            15.1.9.2. Product Portfolio

            15.1.9.3. Profitability by Market Segments

            15.1.9.4. Sales Footprint

            15.1.9.5. Strategy Overview

                15.1.9.5.1. Marketing Strategy

        15.1.10. Squibb Company

            15.1.10.1. Overview

            15.1.10.2. Product Portfolio

            15.1.10.3. Profitability by Market Segments

            15.1.10.4. Sales Footprint

            15.1.10.5. Strategy Overview

                15.1.10.5.1. Marketing Strategy

        15.1.11. Elan Corporation Plc

            15.1.11.1. Overview

            15.1.11.2. Product Portfolio

            15.1.11.3. Profitability by Market Segments

            15.1.11.4. Sales Footprint

            15.1.11.5. Strategy Overview

                15.1.11.5.1. Marketing Strategy

        15.1.12. Eli Lilly and Company

            15.1.12.1. Overview

            15.1.12.2. Product Portfolio

            15.1.12.3. Profitability by Market Segments

            15.1.12.4. Sales Footprint

            15.1.12.5. Strategy Overview

                15.1.12.5.1. Marketing Strategy

        15.1.13. Chugai Pharmaceutical Co. Ltd.

            15.1.13.1. Overview

            15.1.13.2. Product Portfolio

            15.1.13.3. Profitability by Market Segments

            15.1.13.4. Sales Footprint

            15.1.13.5. Strategy Overview

                15.1.13.5.1. Marketing Strategy

16. Assumptions & Acronyms Used

17. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Global Market Value (US$ Mn) Forecast by Region, 2017-2032

Table 02: Global Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 03: Global Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 04: North America Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 05: North America Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 06: North America Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 07: Latin America Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 08: Latin America Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 09: Latin America Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 10: Europe Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 11: Europe Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 12: Europe Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 13: Asia Pacific Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 14: Asia Pacific Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 15: Asia Pacific Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Table 16: MEA Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 17: MEA Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 18: MEA Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01: Global Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 02: Global Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 03: Global Market Value (US$ Mn) by Region, 2022-2032

Figure 04: Global Market Value (US$ Mn) Analysis by Region, 2017-2032

Figure 05: Global Market Value Share (%) and BPS Analysis by Region, 2022-2032

Figure 06: Global Market Y-o-Y Growth (%) Projections by Region, 2022-2032

Figure 07: Global Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 08: Global Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 09: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 10: Global Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 11: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 12: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 13: Global Market Attractiveness by Drug Class, 2022-2032

Figure 14: Global Market Attractiveness by Distribution Channel, 2022-2032

Figure 15: Global Market Attractiveness by Region, 2022-2032

Figure 16: North America Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 17: North America Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 18: North America Market Value (US$ Mn) by Country, 2022-2032

Figure 19: North America Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 22: North America Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 23: North America Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 24: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 25: North America Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 26: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 27: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 28: North America Market Attractiveness by Drug Class, 2022-2032

Figure 29: North America Market Attractiveness by Distribution Channel, 2022-2032

Figure 30: North America Market Attractiveness by Country, 2022-2032

Figure 31: Latin America Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 32: Latin America Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 33: Latin America Market Value (US$ Mn) by Country, 2022-2032

Figure 34: Latin America Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 37: Latin America Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 38: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 40: Latin America Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 41: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 43: Latin America Market Attractiveness by Drug Class, 2022-2032

Figure 44: Latin America Market Attractiveness by Distribution Channel, 2022-2032

Figure 45: Latin America Market Attractiveness by Country, 2022-2032

Figure 46: Europe Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 47: Europe Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 48: Europe Market Value (US$ Mn) by Country, 2022-2032

Figure 49: Europe Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 52: Europe Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 53: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 54: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 55: Europe Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 56: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 57: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 58: Europe Market Attractiveness by Drug Class, 2022-2032

Figure 59: Europe Market Attractiveness by Distribution Channel, 2022-2032

Figure 60: Europe Market Attractiveness by Country, 2022-2032

Figure 61: Asia Pacific Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 62: Asia Pacific Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 63: Asia Pacific Market Value (US$ Mn) by Country, 2022-2032

Figure 64: Asia Pacific Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 67: Asia Pacific Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 70: Asia Pacific Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 73: Asia Pacific Market Attractiveness by Drug Class, 2022-2032

Figure 74: Asia Pacific Market Attractiveness by Distribution Channel, 2022-2032

Figure 75: Asia Pacific Market Attractiveness by Country, 2022-2032

Figure 76: MEA Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 77: MEA Market Value (US$ Mn) by Distribution Channel, 2022-2032

Figure 78: MEA Market Value (US$ Mn) by Country, 2022-2032

Figure 79: MEA Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 80: MEA Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 81: MEA Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 82: MEA Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 83: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 84: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 85: MEA Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032

Figure 86: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032

Figure 87: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032

Figure 88: MEA Market Attractiveness by Drug Class, 2022-2032

Figure 89: MEA Market Attractiveness by Distribution Channel, 2022-2032

Figure 90: MEA Market Attractiveness by Country, 2022-2032

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Immunostimulants Market

Published : July 2022

Healthcare

Autoimmunity Immunoassay Market

Published : April 2017

Healthcare

Immune Checkpoint Inhibitors Market

Published : March 2017

Google translate

Autoimmune Disease Therapeutics Market